The Cigna Group

Q3 2026
Speakers

Nov 5, 2026 · 64 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Ladies and gentlemen, thank you for standing by for the Signat Group's third quarter 2026 results review. At this time, all callers are in a listen-only mode. We will conduct a question and answer session later during the conference ?and review procedures on how to inter queue to ask questions at that time. ?If you should require assistance during the call, please press star zero on your touchstone phone.

As a reminder, ladies and gentlemen, this conference, including the QA session, is being recorded. We'll begin by turning the conference over to Ralph Jacobi. Please go ahead.

Passages & reports (5)
  • Ladies and gentlemen, thank you for standing by for the Signat Group's third quarter 2026 …
  • and
  • review procedures on how to inter queue to ask questions at that time.
  • If
  • you should require assistance during the call, please press star zero on your touchstone p…

Speaker 1

Unverified voice label

Great, thanks. Good morning. Thank you for joining today's call. I'm Ralph Jacoby, Senior Vice President of Investor Relations. With me on the line this morning are Brian Amenko, the Signa Group's President and Chief Executive Officer, and Ann Dennison, Chief Financial Officer. ?In our remarks today, Brian and Ann will cover a number of topics, including our third quarter 2026 financial results and our financial outlook for 2026.

Following their prepared remarks, Brian and Anne will be available for QA. As noted in our earnings release, when describing our financial results, we use certain
financial measures, including adjusted income from operations and adjusted revenues, which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAP. A reconciliation of these measures to the most directly comparable GAAP measures, shareholders' net income, and total revenues, respectively, is contained in today's earnings release, which is posted in the investor relations section of the Signa Group.com.

We use the term labeled adjusted income from operations and adjusted earnings per share on the same basis as our principal measures of financial performance. In our remarks today, we will be making some
forward-looking statements, including statements regarding our outlook for 2026 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. ?

A
description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC. Regarding our results, in the third quarter, we recorded after-tax special item charges of $146 million or $55 per share. Details of the special items are included in our quarterly financial supplement. Additionally, please note that when we make prospective comments regarding financial performance, including our full year 2026 outlook.

We will do so on a basis that includes the potential impact of future share of purchases and anticipated 2026 dividends.

Passages & reports (9)
  • Great, thanks. Good morning. Thank you for joining today's call. I'm Ralph Jacoby, Senior …
  • In
  • our remarks today, Brian and Ann will cover a number of topics, including our third quarte…
  • financial measures, including adjusted income from operations and adjusted revenues, which…
  • contained in today's earnings release, which is posted in the investor relations section o…
  • forward-looking statements, including statements regarding our outlook for 2026 and future…
  • A
  • description of these risks and uncertainties is contained in the cautionary note to today'…
  • special items are included in our quarterly financial supplement. Additionally, please not…

With that, I'll turn the call over to Brian.

Passages & reports (1)
  • With that, I'll turn the call over to Brian.

Speaker unclear

?Thanks, Ralph.

Passages & reports (1)
  • Thanks, Ralph.

Speaker 2

Unverified voice label

Good morning, everyone, and thank you for joining our call. ?I'm pleased to share that the Cygni Group delivered strong performance in the third quarter as we continue executing on our strategy. Today I'll cover our results for the quarter and key drivers, our profitable growth strategy, and how we're advancing toward our long-term EPS growth algorithm of 10 to 14%, which we laid out at our recent investor day, ?as well as how our strategic growth framework positions us to build momentum in 2027.

Then Anne will share additional details about our financial results and outlook for the rest of the year.
?And we'll take your questions. During the quarter, we delivered adjusted revenue of $73.8 billion, adjusted after tax earnings of $2.1 billion, and adjusted earnings per share of $7.98.

Passages & reports (8)
  • Good morning, everyone, and thank you for joining our call.
  • I'm
  • pleased to share that the Cygni Group delivered strong performance in the third quarter as…
  • our recent investor day,
  • as
  • well as how our strategic growth framework positions us to build momentum in 2027. Then An…
  • And
  • we'll take your questions. During the quarter, we delivered adjusted revenue of $73.8 bill…

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 2

work we've done over several years to deliberately shape our portfolio is delivering results, and we are built for the fastest growing areas of healthcare with a proven ability to execute through a dynamic environment. Our strong performance through the first nine months of the year gives us confidence to raise our full-year outlook, and we now expect adjusted earnings per share of at least $30.60.

And importantly, we are building on that strong foundation as we look beyond 2026.
?At our recent Investor Day, we announced our Lead to One vision, which is centered on delivering personalization at scale to improve affordability and the health care experience for every customer and patient we serve. ?Lead to One brings together all of our medical, pharmacy, behavioral health, and specialty care capabilities around the individual.

By responsibly leveraging our data, clinical expertise, and technology, we can identify needs earlier, deliver more personalized support, and improve health outcomes while lowering the total cost of
?care. Our lead to one vision will benefit all customers, and we see a particular opportunity with the most clinically complex patient needs, where health care costs are increasingly concentrated and represent over 50% of total healthcare spending. ?

Lead
to one is underpinned by a clear strategic growth framework comprised of three pillars. First, we will deliver core growth. Second, we will leverage distinct capabilities. And third, we will execute with discipline. ?These three pillars taken together give us a clear path to build on the strength of our business today while creating the next chapter of sustainable growth and greater value for those we serve. ?

Now
let me walk through some of our highlights in the quarter across Evernorth Health Services and Cigna Healthcare. Starting in Evernorth, third quarter earnings were in line with expectations. Our specialty and care services businesses delivered attractive performance, including pre-tax adjusted earnings growth of 15% year over ?year. This was fueled by secular tailwinds and disciplined execution across our specialty pharmacy and distribution capabilities.

We also drove continued strong biosimilar and specialty generic utilization. Today, RevLMid, a widely used oncology drug, is seeing specialty generic adoption rates around 90%.

Passages & reports (16)
  • work we've done over several years to deliberately shape our portfolio is delivering resul…
  • we now expect adjusted earnings per share of at least $30.60. And importantly, we are buil…
  • At
  • our recent Investor Day, we announced our Lead to One vision, which is centered on deliver…
  • Lead
  • to One brings together all of our medical, pharmacy, behavioral health, and specialty care…
  • care. Our
  • lead to one vision will benefit all customers, and we see a particular opportunity with th…
  • Lead
  • to one is underpinned by a clear strategic growth framework comprised of three pillars. Fi…
  • These
  • three pillars taken together give us a clear path to build on the strength of our business…
  • Now
  • let me walk through some of our highlights in the quarter across Evernorth Health Services…
  • year. This
  • was fueled by secular tailwinds and disciplined execution across our specialty pharmacy an…

Across our specialty businesses, we are leveraging our distinct capabilities for patients with complex needs who require a higher level of care, support, and coordination to manage their conditions. ?For example, in our specialty pharmacy at Credo, we have industry leading access with more than 330 highly complex, limited distribution, and exclusive products. This demonstrates the strength of our manufacturer relationships and the trust they place in us to partner in serving some of the most clinically complex patient needs.

Passages & reports (4)
  • Across our specialty businesses, we are leveraging our distinct capabilities for patients …
  • For
  • example, in our specialty pharmacy at Credo, we have industry leading access with more tha…
  • patient needs.

Speaker unclear

?That

Passages & reports (1)
  • That

Speaker 2

access also positions us to capture growth as new specialty therapies come to market.

Passages & reports (1)
  • access also positions us to capture growth as new specialty therapies come to market.

Speaker 2

These highly sterile environments take years to build, license, and operationalize to safely mix and compound some of the most complex medicines. These clean rooms are just one example of the durable competitive advantage in our specialty business that we've constructed over the past few decades. Finally, our expanded distribution channels are unlocking new opportunities. CuraScript SD is a leader in specialty distribution with access to 40 exclusive distribution drugs.

And our recently launched EverNorth Wholesale has begun fulfilling orders to our distribution centers to be able to serve customers.

Passages & reports (2)
  • These highly sterile environments take years to build, license, and operationalize to safe…
  • our expanded distribution channels are unlocking new opportunities. CuraScript SD is a lea…

Speaker unclear

?In

Passages & reports (1)
  • In

Speaker 2

our pharmacy benefit services business in Evernorth, we delivered third quarter pre-tax adjusted earnings of $765 million. We continue to see strong momentum for the 2027 sales season, supporting our core growth, along with strong retention rates in the high 90s. Next, I'd like to spend a moment on our signature model transition. ?We are pioneering this new approach to pharmacy benefits and want you to have further context around current status and why we're so confident in our path. ?

You
can think of our signature implementation in three broad phases. ?Phase one, our design phase, is complete. Announced this time last year, phase one included designing signature, our market defining innovation, driven by core principles of affordability, simplicity, transparency, and value. Inherent in the model is our price assure capability, which is designed to ensure patients pay the lowest available out-of-pocket cost when they fill prescriptions and will save an average of 30% on high cost branded drugs.

Price assure is already in market and being leveraged by about 10% of our current clients.

Passages & reports (9)
  • our pharmacy benefit services business in Evernorth, we delivered third quarter pre-tax ad…
  • on our signature model transition.
  • We
  • are pioneering this new approach to pharmacy benefits and want you to have further context…
  • You
  • can think of our signature implementation in three broad phases.
  • Phase
  • one, our design phase, is complete. Announced this time last year, phase one included desi…
  • out-of-pocket cost when they fill prescriptions and will save an average of 30% on high co…

Speaker unclear

?And

Passages & reports (1)
  • And

Speaker 2

the signature model is consistent with the direction of regulatory changes, including the Consolidated Appropriations Act of 2026 and the Department of Labor's recently finalized PBM fee disclosure ?rule. Phase two, our build phase, is well underway. Currently, we're working on adoption planning alongside market education. Key stakeholders include brokers, pharmaceutical manufacturers, network pharmacy partners, and clients. The work is largely complete for brokers, and we're actively advancing contracts with pharmaceutical manufacturers and network pharmacies.

Phase three our adoption phase is on track.
?The next milestone is the adoption of signature for our Signa Healthcare fully insured book on 1127. Early client conversations for the 2028 benefits year have been encouraging and and indicates strong interest in the model for our broader Evernorth Book of Pharmacy Benefit Services clients. ?And our very strong 2027 selling season reinforces that clients value innovation and see us as a multi-year partner on their pharmacy benefits journey.

Clients see value and signatures focus on patient affordability and transparency, and in how it supports their efforts to meet evolving regulatory requirements and their fiduciary
responsibilities. They also see a model that can encourage adherence with improved health outcomes and workforce productivity. In summary, we're proud of the progress we're making on signature. We've completed phase ?one and are on track to deliver against phases two and three, with broader client adoption expected to ramp in 2028.

We'll share some further detail on the progress across phases two and three during our fourth quarter earnings call. Finally, we continue to leverage our distinct capabilities in pharmacy benefit services to generate
industry leading affordability outcomes, including our deep supply chain expertise, clinical safety checks, and connectivity in the rapidly evolving pharmaceutical market to meet the needs of clients and customers. ?And we're continuing to enhance our technology platforms, better connecting the different components of the pharmacy benefit to create a simpler, more flexible experience for patients and clients.

Passages & reports (14)
  • the signature model is consistent with the direction of regulatory changes, including the …
  • rule.
  • Phase two, our build phase, is well underway. Currently, we're working on adoption plannin…
  • network pharmacies. Phase three our adoption phase is on track.
  • The
  • next milestone is the adoption of signature for our Signa Healthcare fully insured book on…
  • And
  • our very strong 2027 selling season reinforces that clients value innovation and see us as…
  • responsibilities. They also see a model that can encourage adherence with improved health …
  • one
  • and are on track to deliver against phases two and three, with broader client adoption exp…
  • industry leading affordability outcomes, including our deep supply chain expertise, clinic…
  • And
  • we're continuing to enhance our technology platforms, better connecting the different comp…

Speaker unclear

?Turning

Passages & reports (1)
  • Turning

Speaker 2

to Sigma Healthcare, we delivered another quarter of strong growth with results ahead of expectations, with pre-tax-adjusted earnings growth of 15% year a year. Our disciplined pricing, coupled with advanced analytics and insights, enable our steady medical care ratio performance. While medical cost trends continue to be elevated, they are consistent with our expectations and pricing assumptions. This quarter we also benefited from stronger net investment income and favorable SGA performance. ?

We
also introduced new capabilities in Cigna Healthcare in September with the launch of HealthSense, our data and technology powered customer engagement solution that will start with oncology but broaden to other conditions over ?time. By connecting a customer's health needs, benefits, pharmacy coverage, costs, claims, and prior interactions, our clinical teams have context and a more complete picture enabling earlier interventions. ?As a reminder, costs are increasingly concentrated in complex conditions, with 8% of patients generating 55% of total health care spent.

We're excited about the early positive reception to HealthSense from clients and customers and are taking an agile approach
?to launching additional components as they are

Passages & reports (10)
  • to Sigma Healthcare, we delivered another quarter of strong growth with results ahead of e…
  • be elevated, they are consistent with our expectations and pricing assumptions. This quart…
  • We
  • also introduced new capabilities in Cigna Healthcare in September with the launch of Healt…
  • time. By
  • connecting a customer's health needs, benefits, pharmacy coverage, costs, claims, and prio…
  • As
  • a reminder, costs are increasingly concentrated in complex conditions, with 8% of patients…
  • to
  • launching additional components as they are

Speaker unclear

?built. As

Passages & reports (1)
  • built. As

Speaker 2

we look to 2027, we remain confident in the strength of our strategic growth framework and our ability to perform through a dynamic environment. During our fourth quarter call, we will provide our comprehensive 2027 guidance. We continue to expect adjusted earnings per share growth of at least 10% in 2027 off our run rate earnings for our ongoing businesses and remain confident in 2030 adjusted earnings per share of at least $45 that we outlined in our investor ?day.

Today I'll briefly cover the primary tailwinds and headwinds for 2027. Starting with the tailwinds.
?First, in our Sigma Healthcare business, we are driving continued improvement in our stop loss margins. Second, we're pleased with a strong 2027 selling season in both Evernorth and Signa Healthcare. High client retention and new business wins reinforce the strength of our value proposition and innovation and will contribute to attractive enterprise revenue growth in 2027. ?

And
third, our accelerate to one modernization and productivity initiative will drive savings across the enterprise. ?Turning to the headwinds we expect in 2027. First, within Evernorth Pharmacy Benefit Services, the compression of industry rebate pools and lower employer coverage of GLP ones for weight loss, consistent with our commentary from Investor ?Day. Second, within Evernorth Specialty and Care Services, a more limited pipeline of biosimilar and specialty generic launches in the coming year. ?

And
finally, as you'd expect, the known exit from the ACA exchange business will remove that contribution from Signa Healthcare. To ensure our success, we're focused on disciplined execution across the enterprise. ?Part of our DNA is our proven ability to evolve. Throughout our 234 year history, we've continuously adapted to lead through change and innovated to drive what comes next. Across our businesses, we're coupling data and insights with our clinical and analytical expertise, resulting in disciplined pricing, timely patient support, and consultative solutions for clients.

And we're building a future ready, efficient, and effective workforce while optimizing accountability and decision making with our Accelerate to One initiative, all while driving run rate savings of $3 billion by 2030, which you will hear more about from Anne in a few moments.
?Now let me close with a few key takeaways. First, we are generating core growth in each of our three business platforms.

We've deliberately shaped our portfolio with capabilities that are focused on the most attractive subsectors of healthcare where needs and spending are concentrated, with multiple growth engines across specialty and care services and pharmacy
benefit services in Evernorth, along with Signal Healthcare. Second, we are leveraging our distinct capabilities that strengthen our position for the future. Our expertise in complex care, combined with our clinical capabilities, data, advanced analytics, and AI, enables us to deliver greater personalization at scale, improve affordability, and create more value for the people we serve.

You see that strategy coming to life through capabilities like Health Sense, our expanding specialty infrastructure, and continued innovation across our pharmacy businesses. Third, disciplined execution continues to differentiate our company. This quarter, that showed up in
strong client demand, disciplined pricing, stable medical cost trends, continued specialty growth, and our ability to adapt our solutions as the market evolves. ?And as we look to 2027, we have clear visibility into the puts and takes ahead and have multiple levers across the enterprise to deliver against our commitments.

Importantly, we are not dependent on any one single business, market trend, or innovation to deliver our long-term expectations.
?Our third quarter performance reinforces our confidence in our lead-to-one vision and in our long-term strategy, leading to durable, profitable growth and compelling long-term shareholder value creation. ?With that, I'll turn it over to Ann.

Passages & reports (29)
  • we look to 2027, we remain confident in the strength of our strategic growth framework and…
  • off our run rate earnings for our ongoing businesses and remain confident in 2030 adjusted…
  • day.
  • Today I'll briefly cover the primary tailwinds and headwinds for 2027. Starting with the t…
  • First,
  • in our Sigma Healthcare business, we are driving continued improvement in our stop loss ma…
  • enterprise revenue growth in 2027.
  • And
  • third, our accelerate to one modernization and productivity initiative will drive savings …
  • Turning
  • to the headwinds we expect in 2027. First, within Evernorth Pharmacy Benefit Services, the…
  • Day.
  • Second, within Evernorth Specialty and Care Services, a more limited pipeline of biosimila…
  • And
  • finally, as you'd expect, the known exit from the ACA exchange business will remove that c…
  • Part
  • of our DNA is our proven ability to evolve. Throughout our 234 year history, we've continu…
  • and consultative solutions for clients. And we're building a future ready, efficient, and …
  • Now
  • let me close with a few key takeaways. First, we are generating core growth in each of our…
  • benefit services in Evernorth, along with Signal Healthcare. Second, we are leveraging our…
  • improve affordability, and create more value for the people we serve. You see that strateg…
  • strong client demand, disciplined pricing, stable medical cost trends, continued specialty…
  • And
  • as we look to 2027, we have clear visibility into the puts and takes ahead and have multip…
  • Our
  • third quarter performance reinforces our confidence in our lead-to-one vision and in our l…
  • With
  • that, I'll turn it over to Ann.

Speaker 3

Unverified voice label

Thanks, Brian, and good morning, everyone. As Brian mentioned, our third quarter results reflect the strength of our enterprise and the consistency of our execution. ?Through our lead-to-one Envision, we are delivering core growth across a deliberately shaped portfolio of businesses, leveraging our distinct capabilities to deliver greater personalization at scale, particularly for patients with complex conditions, and executing with discipline. That combination of focused strategy and execution continues to translate into strong results.

During the quarter, we delivered adjusted revenues of $73.8 billion, adjusted after tax earnings of $2.1 billion, and adjusted earnings per share of $7.98. With our strong third
quarter performance, we are raising our full year 2026 adjusted earnings per share outlook to at least $30.60. Now turning to our segment results. I'll start with Evernor, where we continue to execute on the strategy Matt Pearlberg and Adam Kalsner outlined at Investor Day to strengthen our specialty leadership while evolving pharmacy benefit services to deliver greater affordability and transparency.

Third quarter 2026 revenues grew 6% year over year to $63.8 billion, and pre-tax adjusted earnings were $1.8 billion.

Passages & reports (6)
  • Thanks, Brian, and good morning, everyone. As Brian mentioned, our third quarter results r…
  • Through
  • our lead-to-one Envision, we are delivering core growth across a deliberately shaped portf…
  • execution continues to translate into strong results. During the quarter, we delivered adj…
  • quarter performance, we are raising our full year 2026 adjusted earnings per share outlook…
  • to strengthen our specialty leadership while evolving pharmacy benefit services to deliver…

Specialty and care services delivered strong performance, with pre-tax adjusted earnings growing 15% year over year to $1.1 billion, in line with expectations. This growth reflects our distinct specialty capabilities across ACO and Curiscript and our clinical expertise and patient support services, which together are driving momentum in our fastest growing business. Consistent with our lead to one strategy, we continue to make specialty care more affordable by accelerating access to lower cost alternatives, which benefit patients and clients while driving growth for the business.

We continue to drive strong adoption of biosimilars led by our $0 patient out-of-pocket offerings for both Biosimilar UMIRA and Stellara. Adoption of new specialty generics continue to ramp during the quarter, including generic RevLomid, where
penetration is now approximately 90%. And finally, income from our investment in SHIALS Health Solutions contributed to the growth in the quarter. Within pharmacy benefit services, pre-tax adjusted earnings were $765 million in line with expectations. ?

As
we outlined in Investor Day, this business is in a period of transition, and our performance continues to reflect the previously discussed renewals and extensions of large client contracts, as well as investments to support the transition to our new signature model. Overall, Evernorps third-quarter results reflect continued growth in our specialty and care services business, powered by our distinct capabilities across both pharmacy and medical benefits, and disciplined execution as we evolve our pharmacy benefit services business towards signature, delivering greater affordability and transparency for patients and clients.

Turning to Sigma Healthcare, where we continue to execute on the strategy Brian Holberson outlined at Investor Day, deepening client relationships and expanding share in the employer market through our integrated medical, pharmacy, and behavioral model, with a particular focus on customers with
complex care needs. We see significant opportunity to improve outcomes and affordability for these customers through more personalized care. Third quarter 2026 adjusted revenues grew 9% year over year to $11.7 billion, and pretext adjusted earnings were $1.2 billion.

Sigma healthcare adjusted earnings were ahead of expectations, primarily driven by favorable net investment income and ongoing operating efficiencies.

Passages & reports (10)
  • Specialty and care services delivered strong performance, with pre-tax adjusted earnings g…
  • expertise and patient support services, which together are driving momentum in our fastest…
  • growth for the business. We continue to drive strong adoption of biosimilars led by our $0…
  • penetration is now approximately 90%. And finally, income from our investment in SHIALS He…
  • As
  • we outlined in Investor Day, this business is in a period of transition, and our performan…
  • continued growth in our specialty and care services business, powered by our distinct capa…
  • clients. Turning to Sigma Healthcare, where we continue to execute on the strategy Brian H…
  • complex care needs. We see significant opportunity to improve outcomes and affordability f…
  • $1.2 billion. Sigma healthcare adjusted earnings were ahead of expectations, primarily dri…

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 3

medical care ratio for the third quarter was 85%, in line with expectations as trend remained elevated but stable, and costs remained consistent with our pricing assumptions. Total medical customers have grown 2% year to date to 18.5 million customers. We continue to see strong growth in our select segment, which serves U.S. employers with fewer than 500 employees, with medical customers up 5% year-to-date, reflecting market share gains that we highlighted at Investor Day.

Overall, Signa Healthcare continues to deliver strong growth driven by our distinct capabilities along with
discipline pricing and expense management. Now turning to our updated outlook for 2026. The strength of our third quarter performance gives us the confidence to increase our full year adjusted earnings per share outlook to at least $30.60. Within EverNorth, we continue to expect full year pre-tax adjusted earnings of at least $6.9 billion.

Within Sigma Healthcare, we are raising our full year pre-tax adjusted earnings outlook to at least $4.6 billion, and with greater visibility into full year performance, we are updating our full year
MCR outlook, maintaining our prior midpoint of 84.2%, and tightening our range to plus or minus 25 basis points. Turning to our 2026 capital management position, ?the third quarter operating cash flow was $2.6 billion, and we continue to expect strong cash flow from operations in the fourth quarter, consistent with the pattern we observed in the prior two years.

During the quarter, we reduced our debt-to-capitalization ratio by approximately 100 basis points to 41.8%
as of September 30th. And we remain on track to achieve our long-term target of approximately 40% by year ?end. Additionally, in the third quarter, we were purchased approximately 900,000 shares of common stock for approximately $250 million.

Passages & reports (10)
  • medical care ratio for the third quarter was 85%, in line with expectations as trend remai…
  • growth in our select segment, which serves U.S. employers with fewer than 500 employees, w…
  • discipline pricing and expense management. Now turning to our updated outlook for 2026. Th…
  • continue to expect full year pre-tax adjusted earnings of at least $6.9 billion. Within Si…
  • MCR outlook, maintaining our prior midpoint of 84.2%, and tightening our range to plus or …
  • the
  • third quarter operating cash flow was $2.6 billion, and we continue to expect strong cash …
  • as of September 30th. And we remain on track to achieve our long-term target of approximat…
  • end.
  • Additionally, in the third quarter, we were purchased approximately 900,000 shares of comm…

Now turning to some early thoughts on 2027, I'll provide some additional directional comments building on the headwinds and tailwinds Brian discussed. First, our 2026 run rate earnings. As you think about the appropriate starting point, it's important to consider our previously announced exit from the ACA exchange market. For 2026, we continue to expect our ACA exchange business to generate positive margins, though below our 4-6% margin target.

And we expect some runoff and stranded overhead costs to remain next year. Based on our current estimates, this represents an
approximately $200 million headwind in Signa Healthcare, resulting in a 2026 run rate adjusted EPS of approximately $30. Regarding our outlook for our business segments and Cigna Healthcare, we expect another year of strong growth with adjusted income from operations growing within our long term target of 6 to 9% of our reported 2026 results, or above the high end of our long term target after adjusting for our exit from the ACA exchange market.

This reflects strong core growth, continued momentum and select where our distinct capabilities
position us to gain market share, and disciplined execution in our pricing to improve margin and stop loss. ?In our specialty and care services business, despite more limited biosimilar and specialty generic launches in 2027, we still expect adjusted earnings to grow within the 8 to 12% long term target range, though towards the low end.

In pharmacy benefit services, as Brian mentioned, and as we
discussed at our investor day, we anticipate near term headwinds, including industry wide compression and gross rebates, and lower employer coverage of GLP 1s for weight loss, consistent with our prior comments. Taken together, we expect Evernote earnings to be up low single digits in 2027.

Passages & reports (8)
  • Now turning to some early thoughts on 2027, I'll provide some additional directional comme…
  • exchange market. For 2026, we continue to expect our ACA exchange business to generate pos…
  • approximately $200 million headwind in Signa Healthcare, resulting in a 2026 run rate adju…
  • growing within our long term target of 6 to 9% of our reported 2026 results, or above the …
  • position us to gain market share, and disciplined execution in our pricing to improve marg…
  • In
  • our specialty and care services business, despite more limited biosimilar and specialty ge…
  • discussed at our investor day, we anticipate near term headwinds, including industry wide …

Regarding our capital management in 2027, consistent with the deployment framework we outlined at Investor Day, we continue to view share repurchase as an attractive use of capital. As I mentioned earlier, we expect to achieve our debt-to-capital target of approximately 40% by year-end 2026, and we expect greater flexibility in capital deployment next year. In summary, we remain confident in delivering at least 10% adjusted earnings for share growth in 2027 off of our 2026 run rate of approximately $30, which reflects our exit from the ACA exchange business. ?

We
believe this is a prudent starting point, and we look forward to providing further guidance on our fourth quarter call. Underpinning our confidence in our ability to deliver in 2027 and through 2030 is accelerate to one. This modernization and productivity initiative, which we announced at our recent investor day, will lower our cost to serve and create operating leverage for the enterprise. We expect this initiative to contribute $3 billion in gross savings by 2030.

Notably, we expect to reinvest some of these savings back into the business to fund growth and innovation, while a portion will benefit operating
results. This initiative further reinforces our confidence in our ability to deliver attractive earnings growth in 2027 and over the long term, and we look forward to providing periodic updates on our progress.

Passages & reports (6)
  • Regarding our capital management in 2027, consistent with the deployment framework we outl…
  • flexibility in capital deployment next year. In summary, we remain confident in delivering…
  • We
  • believe this is a prudent starting point, and we look forward to providing further guidanc…
  • will lower our cost to serve and create operating leverage for the enterprise. We expect t…
  • results. This initiative further reinforces our confidence in our ability to deliver attra…

Speaker unclear

?Now

Passages & reports (1)
  • Now

Speaker 3

to recap, our third quarter results reflect strong core growth, our distinct capabilities in both EverNorth and Cigna Healthcare, and disciplined execution across the enterprise. ?We are pleased with our year-to-day performance and confident in our increased full year 2026 adjusted earnings per share outlook of at least $30.60. And we remain confident in our long-term framework of 10 to 14% average annual adjusted earnings per share growth and at least $45 of adjusted earnings per share in 2030, which we discussed at Investor Day.

With that, we'll turn it over to the operator for the QA portion of the call.

Passages & reports (4)
  • to recap, our third quarter results reflect strong core growth, our distinct capabilities …
  • We
  • are pleased with our year-to-day performance and confident in our increased full year 2026…
  • least $45 of adjusted earnings per share in 2030, which we discussed at Investor Day. With…

Speaker 0

Ladies and gentlemen, at this time if you do have a question, please press star one on your touchstone phone. If someone asks your question ahead of you, you can remove yourself from the queue by pressing star to. Also, if you're using a speakerphone, please pick up your handset before pressing the buttons. One

Passages & reports (1)
  • Ladies and gentlemen, at this time if you do have a question, please press star one on you…

Questions & answers

Speaker 0

moment, please, for the first question. Our first question comes from Lisa Gill with JP Morgan. You may ask your question.

Passages & reports (1)
  • moment, please, for the first question. Our first question comes from Lisa Gill with JP Mo…

Speaker 4

Unverified voice label

Thanks very much. Good morning. Thank you for all the detail, Brian and Ann. I really just want to dig into a few things when we think about the progression in the PDF side of the business. I heard you talk about, you know, kind of the next stage where you're building adoption, educating the market, signing manufacturing and pharmacy agreements. Can you help us to understand one, what that looks like, two, what the progression looks like in 27?

And you talked about low single digits overall for Evernorth. So it doesn't feel like there's a big progression versus what we're seeing here in 26 and
the PBS uh segment specifically. So if you could just help us to bridge that and and talk a little bit about how you make um progress in in the contracting

Passages & reports (3)
  • Thanks very much. Good morning. Thank you for all the detail, Brian and Ann. I really just…
  • market, signing manufacturing and pharmacy agreements. Can you help us to understand one, …
  • the PBS uh segment specifically. So if you could just help us to bridge that and and talk …

Speaker unclear

?uh

Passages & reports (1)
  • uh

Speaker 2

good morning lisa i'll start and if there's anything you want to add feel free to uh to jump in here ?uh so i think a few components to your question there starting with signature and then i believe your your reference to the uh ?the low single digit was the Ebernorth aggregate income growth um expectation that we outlined ?there um but just relative to where we are with signature first off we're we're proud to lead the industry with our new signature pharmacy benefits offering.

If you step back, affordability continues to be the number one challenge facing patients, with the affordability of prescription drugs being a primary pain point. And that's particularly acute
for high-cost branded prescriptions, which represent just 10% of all prescriptions in America, ?but 90% of the total drug spending. And when you look back, one of the great success stories in American healthcare is the way PBMs have led generic adoption to now reach some 90% of all prescriptions at very affordable price points.

So the next frontier is attacking the remaining 10% of prescriptions that are in
very high cost branded drugs and represent some 90% of drug spending. So our signature model is designed to attack that 10% ?of high cost brand drugs and provide a simple, fee-based, transparent solution for clients and customers. ?So as I talked about earlier, there are three phases of our signature model implementation.

Maybe I'll just share a little bit more color on some of those components. Phase one was the design phase, which is now complete, which was the decision we made to move to a simple future fee-based no rebate model. And
this architecture leverages the same value creators for clients and customers, meaning procuring drugs at the most affordable ETA costs, wrapping those with clinical programs that drive adherence and administering complex benefit plan designs.

Phase two is our build phase, and I think your question was pointing at this specifically in terms of where are
we with manufacturer network contracts. This is actively underway. Our team's doing quite a bit of heavy lifting here relative to recontracting as we speak. We'll talk about more details on this on our fourth quarter call, but we're actively negotiating with the largest pharmaceutical manufacturers as we speak to get the signature contracts fully landed.

This phase also includes all the technology enhancements in the implementation readiness work that's uh that's required. And finally, for the upcoming sales season, we've been working hard to educate brokers, the employer community, current clients, and prospects on what the signature model
entails. ?And then phase three, as I alluded to earlier, is our adoption phase, and that's well on track. The next milestone is our Signa Healthcare Fully Insured book, which will adopt signature 1127, and then the broader ramp will transpire throughout 2028.

So big picture, strong receptivity from each of those different stakeholders. We continue to
expect 28 will be the year where we see significant adoption across the broader EverNorth book of business. The second part of your question, as Ann indicated in our comments, we expect Evernorth 27 income to be up low single digits. We expect our specialty and care business to be within our long-term growth algorithm of 8 to 12%, albeit the lower end, which implies our pharmacy benefit services income will be down single digits in 27% from where we are in 26 due to the industry wide pressure on gross rebate pools as well as a downtick in the percentage of employers covering GLP1s for weight management.

Passages & reports (23)
  • good morning lisa i'll start and if there's anything you want to add feel free to uh to ju…
  • uh
  • so i think a few components to your question there starting with signature and then i beli…
  • the
  • low single digit was the Ebernorth aggregate income growth um expectation that we outlined
  • there
  • um but just relative to where we are with signature first off we're we're proud to lead th…
  • for high-cost branded prescriptions, which represent just 10% of all prescriptions in Amer…
  • but
  • 90% of the total drug spending. And when you look back, one of the great success stories i…
  • very high cost branded drugs and represent some 90% of drug spending. So our signature mod…
  • of
  • high cost brand drugs and provide a simple, fee-based, transparent solution for clients an…
  • So
  • as I talked about earlier, there are three phases of our signature model implementation. M…
  • this architecture leverages the same value creators for clients and customers, meaning pro…
  • we with manufacturer network contracts. This is actively underway. Our team's doing quite …
  • contracts fully landed. This phase also includes all the technology enhancements in the im…
  • entails.
  • And
  • then phase three, as I alluded to earlier, is our adoption phase, and that's well on track…
  • expect 28 will be the year where we see significant adoption across the broader EverNorth …
  • of 8 to 12%, albeit the lower end, which implies our pharmacy benefit services income will…

As we talked about on prior calls, 26 and 27 are transitional years ?for our pharmacy benefit services business, and we continue to expect at least 4% up to 4% compounded income growth from 26 to 30 in the PBS business and continue to expect at least $45 per share of 2030 adjusted EPS. So a lot in there. Hopefully you got all the components of your

Passages & reports (3)
  • As we talked about on prior calls, 26 and 27 are transitional years
  • for
  • our pharmacy benefit services business, and we continue to expect at least 4% up to 4% com…

Speaker unclear

?question.

Passages & reports (1)
  • question.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. And this question comes from Kevin Fishbeck with Bank of America. You may ask your question.

Passages & reports (1)
  • you. And this question comes from Kevin Fishbeck with Bank of America. You may ask your qu…

Speaker 5

Unverified voice label

Uh great. Thanks. I guess just uh kind of two follow-up questions on the on the guidance uh for 2027. Um I guess first the the sixty cent drag, um, it sounds like some of it's just core earnings and some of it is kind of stranded costs. Can you quantify how much that 60 cents might be recaptured in 28 and beyond? And then as far as the um ?the headwind to 2027 regarding the uh the fewer launches ?on the specialty side, is is there any early look on 28?

Is that a more normal year in your view, or is that uh also a little bit lower? Thanks.

Passages & reports (6)
  • Uh great. Thanks. I guess just uh kind of two follow-up questions on the on the guidance u…
  • cents might be recaptured in 28 and beyond? And then as far as the um
  • the
  • headwind to 2027 regarding the uh the fewer launches
  • on
  • the specialty side, is is there any early look on 28? Is that a more normal year in your v…

Speaker unclear

?Uh good

Passages & reports (1)
  • Uh good

Speaker 2

morning, Kevin. I'll have Ann take the first part of your question in terms of the individual exchange exit and the impact on 26-27, how to think about 28, and then I'll take the second piece relative to the specialty and care and

Passages & reports (1)
  • morning, Kevin. I'll have Ann take the first part of your question in terms of the individ…

Speaker 3

great. Morning, Kevin. So just on the ACA, just to level set, the results for our the quarter this quarter were largely in line with expectations. And so I mentioned this in my prepared remarks, but as a reminder, we expect the business to be profitable this year, but with margins a little below our 4-6% target range. So there's two things to think about as we look at the impact of the ACA exchange exit on our 27 outlook.

The first is what the business contributes today. And then the second is the stranded overhead and other costs that come along with exiting a business, which is what you'd
expect. So when you put those two together based on our current projections, we expect an all-in headwind of about 200 million from exiting the exchange market. As we it was specifically related to your question on recapture in 28, of course, as we always do, we'd be look looking to get out any of the runoff costs and the stranded overhead that remains once we've exited the business.

Passages & reports (4)
  • great. Morning, Kevin. So just on the ACA, just to level set, the results for our the quar…
  • 4-6% target range. So there's two things to think about as we look at the impact of the AC…
  • expect. So when you put those two together based on our current projections, we expect an …
  • the runoff costs and the stranded overhead that remains once we've exited the business.

Speaker unclear

?Thanks,

Passages & reports (1)
  • Thanks,

Speaker 2

Ed. And on the second component of your question, Kevin, in terms of the headwind that we flagged relative to the specialty and care business, it's specifically 2027 is a bit of a slower year for new biosimilar and specialty generics. If you're going to step back and look over a longer period of time, new introduction of biosimilars and specialty generics has ?been a great success story for American healthcare.

And over the past three years, Himira having biosimilar competition in 24, Stellara having biosimilar competition in 25, generic Revel Minute having supply constraints eased in 26. Each of those provided tailwinds for 24, 25, and 26. And when you look back at our specialty
in care business, between 2023 and 26, we've compounded income growth of 13%, which is above our long term growth algorithm for specialty in care.

Now, from year to year, there'll be some ebb and flow on the timing and magnitude of drugs that will see new biosimilar and specialty generic competition. So for 27
specifically, again, the pipeline indicates less material new biosimilars or specialty generics being introduced. But I would view that as a temporary slowdown. As we look ahead to 28, 29, and 30, there are several biosimilars coming to market for drugs often covered under the medical benefit.

So think oncology drugs, MS drugs, and we're
preparing for these introductions. Now stepping back from all of this, we're actively encouraging the approval and adoption of these low-cost alternatives. It's a great means to improve affordability. And finally, the continued momentum across our broader specialty and care portfolio allows us to overcome this headwind to specialty growth. And as Ann noted, we do expect 2027 specialty and care earnings growth near the low end of our long-term income growth algorithm of 8 to 12% per year, which speaks to the strength of our broad suite of specialty capabilities ?as well as our expertise in serving patients with the most complex healthcare needs.

Hopefully that helps.

Passages & reports (10)
  • Ed. And on the second component of your question, Kevin, in terms of the headwind that we …
  • new introduction of biosimilars and specialty generics has
  • been
  • a great success story for American healthcare. And over the past three years, Himira havin…
  • in care business, between 2023 and 26, we've compounded income growth of 13%, which is abo…
  • specifically, again, the pipeline indicates less material new biosimilars or specialty gen…
  • preparing for these introductions. Now stepping back from all of this, we're actively enco…
  • we do expect 2027 specialty and care earnings growth near the low end of our long-term inc…
  • as
  • well as our expertise in serving patients with the most complex healthcare needs. Hopefull…

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. Our next question comes from AJ Rice with UBS. ?You may ask your question.

Passages & reports (3)
  • you. Our next question comes from AJ Rice with UBS.
  • You
  • may ask your question.

Speaker 6

Unverified voice label

Uh thanks. Hi everybody. Just to make sure I understand, so as you as under use deploy the new signature model next year to your fully insured book, you didn't mention that as a headwind for either side of the business. Is there any short-term pressure either on the insurance side or on the Evernote side that then abates over time as it gets uh more mature?

And uh just also on the signature model, um, you you did reference various regulatory things, the PBM reform legislation from January, the Department of Labor
announcement. Are you naturally going to comply with all of ?the provisions there as you move to the signature model, or is there anything incrementally from an investment perspective you need to do to comply with those as they phase in by 28 and so forth?

Passages & reports (5)
  • Uh thanks. Hi everybody. Just to make sure I understand, so as you as under use deploy the…
  • side or on the Evernote side that then abates over time as it gets uh more mature? And uh …
  • announcement. Are you naturally going to comply with all of
  • the
  • provisions there as you move to the signature model, or is there anything incrementally fr…

Speaker unclear

?A

Passages & reports (1)
  • A

Speaker 2

few different components in there. Relative to the first piece of your question, the signature model implementation for our fully insured business for 1127 with Insigna Healthcare, as I mentioned earlier ?in Lisa's question, fully on track to implement that effective January 1st. To your point, that is not a headwind relative to 27. The reason for that is it's since it's fully insured business, any change in economics is essentially in the price.

It's in the price that we've implemented through our standard underwriting
process as we go through case by case, client by client, and put the appropriate price in place. So the 27 headwinds we talked about specifically for PBS are limited ?to the GLP1 weight management coverage ticking down ?in our employer book, and secondarily the compression on industry-wide rebates. ?So again, 26, 27, think of those as transitional years for PBS, 28, 29, 30.

We'll see income growth over that time period.
?On the second piece of your question, relative to some of the PBM rules and regulations and reform changes that have gone through most recently, ?the Department of Labor PBM transparency rule was issued just a few weeks ago, and really this issue or this rule speaks to the primary challenge of our healthcare system, which again is affordability.

And we support the underlying spirit implied by this rule, specifically the use of objective, data driven, transparent information
?in order to drive more educated purchasing and utilization. That said, we think it's very unlikely that this rule will result in lower prescription drug spending. There's some redundancy in the DOL rule and the Consolidated Appropriations Act, and there's some areas where the two are actually contradictory.

Our team is actively engaging to drive clarity
on these issues for the benefit of our clients and customers. ?Now, as it relates to the DOL rule itself, we will of course comply with the requirements. This will add some administrative cost and burden to the system, but you should not think of that as a material amount of new spending, something that I would view is normal course for our PBS business.

But again,
coming back to our signature model, that is our one bold way that we're taking action ourselves to drive change in the system with a focus on affordability and a focus on actionable transparency. This model also provides that patient guarantee of the lowest possible out-of-pocket cost when they fill a prescription. Finally, the signature model is designed to comply with evolving regulations, including both the CAA and the DOL transparency rule while reducing fiduciary risk for employers who adopt the model.

So we're very excited about the signature model. Looking forward to its scaling across the Ever North Book starting in 28. Thanks for the question.

Passages & reports (21)
  • few different components in there. Relative to the first piece of your question, the signa…
  • in
  • Lisa's question, fully on track to implement that effective January 1st. To your point, th…
  • process as we go through case by case, client by client, and put the appropriate price in …
  • to
  • the GLP1 weight management coverage ticking down
  • in
  • our employer book, and secondarily the compression on industry-wide rebates.
  • So
  • again, 26, 27, think of those as transitional years for PBS, 28, 29, 30. We'll see income …
  • On
  • the second piece of your question, relative to some of the PBM rules and regulations and r…
  • the
  • Department of Labor PBM transparency rule was issued just a few weeks ago, and really this…
  • in
  • order to drive more educated purchasing and utilization. That said, we think it's very unl…
  • on these issues for the benefit of our clients and customers.
  • Now,
  • as it relates to the DOL rule itself, we will of course comply with the requirements. This…
  • coming back to our signature model, that is our one bold way that we're taking action ours…
  • model is designed to comply with evolving regulations, including both the CAA and the DOL …

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. And this question comes from Justin Lake with Wolf Research. You remind you helping me after a question.

Passages & reports (1)
  • you. And this question comes from Justin Lake with Wolf Research. You remind you helping m…

Speaker 2

Thanks,

Passages & reports (1)
  • Thanks,

Speaker unclear

?good morning. Uh

Passages & reports (1)
  • good morning. Uh

Speaker 5

on the three

Passages & reports (1)
  • on the three

Speaker 7

Unverified voice label

headwinds to Evernorth next year, are all three about similar sized, or maybe you can rank order them for us in terms of impact. And then you didn't mention investment games in 2026 as a headwind for the healthcare business next year. By my math, it looks like it could be north of $100 million. How should we think about that? Thanks.

Passages & reports (2)
  • headwinds to Evernorth next year, are all three about similar sized, or maybe you can rank…
  • How should we think about that? Thanks.

Speaker 2

Good morning, Justin. I'll start. And if you could pick up on the how to think about the quant on the three headwinds as well as the question Justin asked about the investment income. We're going to wait until the fourth quarter to get into our detailed guidance relative to sub segment and segment guides for 27. What we're trying to do today was give you a little bit of texture in terms of how to think about the 27 versus 26 income trajectory for each of our businesses.

But as I said earlier to the question that Kevin asked on specialty, we will still be within our 8 to
12 percent income growth algorithm, albeit at the lower end. So that headwind in the big picture is more than offset by the underlying strong secular growth that we see in specialty by the continued expansion of our distribution capabilities, by the improvement in our cost to fill through through initiatives like our pharmacy forward.

Passages & reports (3)
  • Good morning, Justin. I'll start. And if you could pick up on the how to think about the q…
  • for 27. What we're trying to do today was give you a little bit of texture in terms of how…
  • 12 percent income growth algorithm, albeit at the lower end. So that headwind in the big p…

So big picture, you should not think of that as a substantial headwind in a dollars and cents standpoint. And then the PBS headwind that we made reference to contributes to the total income being down single digits 27 relative to 26. So that gives you a bit of just ballpark dimensioning of how to think about the magnitude. And can you pick up anything else on the headwinds and then the investment income component?

Passages & reports (2)
  • So big picture, you should not think of that as a substantial headwind in a dollars and ce…
  • think about the magnitude. And can you pick up anything else on the headwinds and then the…

Speaker 3

Sure, just to Brian's point around pharmacy benefits services and the headwinds there. ?Um, we look forward to quantifying you know the specific numbers coming out of the fourth quarter. Um you can think about those the two headwinds referenced as ?you know relative relatively equal. Uh on the investment gains in Signa Healthcare for this year, um, I I would not characterize that as a headwind going into 2027.

Passages & reports (5)
  • Sure, just to Brian's point around pharmacy benefits services and the headwinds there.
  • Um,
  • we look forward to quantifying you know the specific numbers coming out of the fourth quar…
  • you
  • know relative relatively equal. Uh on the investment gains in Signa Healthcare for this ye…

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. Our next question comes from Scott Fidel with Goldman Sachs. Let me ask your question.

Passages & reports (1)
  • you. Our next question comes from Scott Fidel with Goldman Sachs. Let me ask your question…

Speaker 6

Hi, uh thanks, um, and uh good morning. Um wanted to just uh ask about um the uh the new initiative, the lead to one uh that you discussed at the investor day and and I know it sounds like you know already there's um sort of execution on that that that's going on um within the company and ?and Brian and Ed maybe maybe just um you know in particular um if you can give us any visibility into ?a level of run rate savings that you expect to potentially be accrued into the 27 outlook that you're contemplating and and the potential you know sort of key drivers of that.

And then also just any one time costs that we may anticipate may hit the gap in uh PL just in the back
half of this year or into next year as you implement uh workforce rationalization and and and other

Passages & reports (7)
  • Hi, uh thanks, um, and uh good morning. Um wanted to just uh ask about um the uh the new i…
  • within the company and
  • and
  • Brian and Ed maybe maybe just um you know in particular um if you can give us any visibili…
  • a
  • level of run rate savings that you expect to potentially be accrued into the 27 outlook th…
  • half of this year or into next year as you implement uh workforce rationalization and and …

Speaker 7

elements

Passages & reports (1)
  • elements

Speaker 1

of uh the lead to one strategy. Thanks.

Passages & reports (1)
  • of uh the lead to one strategy. Thanks.

Speaker 2

Good morning Scott I'll start and then end if you could pick up um So Scott referenced lead to one. I think he was bridging over to our accelerate to one initiative as well in his question relative to the $3 billion of run rate saved that we expect to see by 2030. So step back, lead to one is our vision for the future, which is essentially driving personalization at scale.

We see
?the emergence of data, modern technologies, advanced analytics, AI allowing us to drive personalization in ways that we couldn't even three, five years ago. ?And we're excited to do that across all the customers and patients we served with a particular emphasis on those who have the most clinically complex healthcare needs, which, as I said in my earlier comments, that now represents 55% of total spending, even though it's just 8% of patients.

Our accelerate to one initiative specifically
is using a combination of technology, workforce effectiveness, vendor rationalization in order to drive that $3 billion of run rate save by 2030, $3 billion of gross run rate savings by 2030. And can you pick up a little bit in terms of how to think about ?the timing, the emergence investment spend of that part in Scott's question?

Passages & reports (9)
  • Good morning Scott I'll start and then end if you could pick up um So Scott referenced lea…
  • back, lead to one is our vision for the future, which is essentially driving personalizati…
  • the
  • emergence of data, modern technologies, advanced analytics, AI allowing us to drive person…
  • And
  • we're excited to do that across all the customers and patients we served with a particular…
  • is using a combination of technology, workforce effectiveness, vendor rationalization in o…
  • the
  • timing, the emergence investment spend of that part in Scott's question?

Speaker 3

Sure. So as Brian, as Brian mentioned, $3 billion of gross run rate savings. We're focused on three areas: automation and process modernization, talent effectiveness, and how we manage our suppliers, partners, and vendors. All of this is enabled by technology and AI, continuous improvement, and a lot of execution rigor. So the goal is twofold. We're going to fund a reinvestment in the business, so not all of it's going to fall to the bottom line.

But also we want to support our 10 to 14% long-term adjusted GPS growth commitment. So ultimately, this is going to help us reduce our cost to serve, create operating leverage, be more
competitive, and have the capacity to keep investing in the growth. In terms of where the savings come from, we expect roughly 70 to 80% of that, you know, $3 billion in growth savings to come from automation, modernization, and talent effectiveness, and the remaining 20 to 30 from improvements in the vendor space.

Passages & reports (3)
  • Sure. So as Brian, as Brian mentioned, $3 billion of gross run rate savings. We're focused…
  • twofold. We're going to fund a reinvestment in the business, so not all of it's going to f…
  • competitive, and have the capacity to keep investing in the growth. In terms of where the …

So we're targeting those savings over the five-year period that began this year. We look forward to providing some more color on the shaping and cadence in the fourth quarter earnings call. And I would just point to on your questions specifically, Scott, related to the costs. The costs that are that in order to execute this are reflected in the strategic optimization program disclosures that will come as part of the queue.

And I would describe them as mostly concentrated on the employee side, severance, and other sort of one-time costs in order to execute some of the savings that we're doing this
year that will carry into next

Passages & reports (3)
  • So we're targeting those savings over the five-year period that began this year. We look f…
  • execute this are reflected in the strategic optimization program disclosures that will com…
  • year that will carry into next

Speaker unclear

?year. Thank

Passages & reports (1)
  • year. Thank

Speaker 0

you. Our next question comes from Jason Casoda with Googling Hype Securities. You may ask your question.

Passages & reports (1)
  • you. Our next question comes from Jason Casoda with Googling Hype Securities. You may ask …

Speaker 6

Great, thanks.

Passages & reports (1)
  • Great, thanks.

Speaker unclear

?Good morning. I wanted to ask a little bit more on EverNorth for 2027. One of the headwinds for PBS segment this year was lower customer script growth due to declines in client plan membership. I guess I'm just curious how you're thinking about that paradigm for

Passages & reports (1)
  • Good morning. I wanted to ask a little bit more on EverNorth for 2027. One of the headwind…

Speaker 6

2027. ?Uh if ?you're assuming some

Passages & reports (5)
  • 2027.
  • Uh
  • if
  • you're assuming
  • some

Speaker unclear

?level of headwind there, that's

Passages & reports (1)
  • level of headwind there, that's

Speaker 6

perhaps ?more than offset

Passages & reports (3)
  • perhaps
  • more than
  • offset

Speaker unclear

?by the uh strong 2027 selling season. Um just any color around that would be uh

Passages & reports (1)
  • by the uh strong 2027 selling season. Um just any color around that would be uh

Speaker 6

helpful.

Passages & reports (1)
  • helpful.

Speaker unclear

?Thanks.

Passages & reports (1)
  • Thanks.

Speaker 2

Appreciate the question there. And you're right, relative to 26, we've seen some decline in the pharmacy benefit services business, both in terms of scripts and overall customer counts. I I just would remind everyone, script counts are not really a great indicator of the financial health or success of this business anymore, particularly as specialty drugs have proliferated, representing a small percentage of prescriptions, but over half of total drug spending.

Another reminder is we serve many health plan clients, and our customer and script volumes are partially dependent upon their own membership growth or decline. So year to date, we did see some reduction in volumes
?from our Evernorth health plan clients specifically, partially driven by how some approach their Medicare or Medicaid products and pricing strategies. All that was broadly in line with expectations.

And as we indicated, our overall Evernorth business delivered solid financial performance through the third quarter
?of 26, and we're pleased to reaffirm the full-year outlook for Evernorth, incorporating all of those dynamics. As it relates to 27 and how to think about this dynamic relative to the selling season, we're tracking toward retention in the high 90s, as I indicated earlier, similar to what we saw in 26, consistent with historical norms.

Additionally, our 27 new business performance is very strong. We're tracking to at least two million new PBS customers in 2027 with that new business written at targeted profit levels.
?And that's been generated from a combination of traditional PBM competitors as well as some smaller alternate PBMs. ?And as I indicated earlier, our new signature model is generating considerable interest both from existing clients as well as prospects as we look to scale in in 28 and beyond.

All this is evidence that our clients see us as a multi-year thought partner as they prepare for future changes in their pharmacy benefit programs.
So taken all together, these factors have been incorporated into the outlook that Ann introduced this morning. And as I mentioned in one of my earlier comments, enterprise revenue for the entire Signet group is on track for an attractive rate of growth here in 27.

Thanks for the question.

Passages & reports (12)
  • Appreciate the question there. And you're right, relative to 26, we've seen some decline i…
  • specialty drugs have proliferated, representing a small percentage of prescriptions, but o…
  • from
  • our Evernorth health plan clients specifically, partially driven by how some approach thei…
  • of
  • 26, and we're pleased to reaffirm the full-year outlook for Evernorth, incorporating all o…
  • norms. Additionally, our 27 new business performance is very strong. We're tracking to at …
  • And
  • that's been generated from a combination of traditional PBM competitors as well as some sm…
  • And
  • as I indicated earlier, our new signature model is generating considerable interest both f…
  • So taken all together, these factors have been incorporated into the outlook that Ann intr…

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. Our next question comes from Charles Ree with T.D. Cowan. You may ask your question.

Passages & reports (1)
  • you. Our next question comes from Charles Ree with T.D. Cowan. You may ask your question.

Speaker 1

Yeah,

Passages & reports (1)
  • Yeah,

Speaker unclear

?th thanks for taking the question.

Passages & reports (1)
  • th thanks for taking the question.

Speaker 5

You know, ?and uh as you've ?kind of talked about

Passages & reports (5)
  • You know,
  • and uh
  • as you've
  • kind
  • of talked about

Speaker unclear

?340B here, um uh it's not including the headwinds for specialty care and services. Can you help us understand a little bit

Passages & reports (1)
  • 340B here, um uh it's not including the headwinds for specialty care and services. Can you…

Speaker 6

why

Passages & reports (1)
  • why

Speaker unclear

?this might be a little bit

Passages & reports (1)
  • this might be a little bit

Speaker 6

impactful to ?you guys here versus ?maybe some of your peers?

Passages & reports (5)
  • impactful to
  • you guys here
  • versus
  • maybe some of
  • your peers?

Speaker 2

Morning, Charles. Appreciate the question. Maybe I'll start with a little bit of background on the program and how we participate and the courier question on the 27 implications. The 340B program has been in place since the early 90s, as you ?know, designed to support access to care for vulnerable patients by allowing those hospitals who serve them to purchase drugs essentially at a lower cost.

And this remains a critical lifeline for many rural and safety net net hospitals. Over the years, we've seen the program experience changes around eligibility, contract pharmacy access, manufacturer
participation, but it has endured given the criticality of the program's underlying purpose to support those rural and safety net hospitals. The way we participate in the 340B program is multifaceted. The most direct way is through a credo, where we serve as a contract pharmacy in the 340B program.

Now, importantly, our total
number of 340B contract pharmacies is far below that of the large retail pharmacy chains. ?So our exposure as a result is a small fraction of what those competitors would have or what those pharmacy chains would have. Overall, you should think of a Credo's participation as a 340B contract pharmacy as being ?a relatively small contributor to overall Evernorth earnings.

I'd also note that the contribution of 340B is reflected within the specialty and care portion of EverNorth specifically. Now, as it relates to 27, there will be some modest downward pressure on our 27 results from the evolved 340B program requirements, but it's just not
significant enough for us to call it out as a substantial headwind. And the continued momentum across our broader specialty and care portfolio, as I described earlier, strong secular growth, distribution expansion, cost of fill improvements, allows us to generate income growth that will be near the low end of our long term growth algorithm for specialty and care of 8 to 12% per year.

So we'll be toward the lower end of that. Again, all that speaks to the strength of the broad suite of capabilities we have across specialty and our expertise in serving those individuals with the most complex healthcare needs. So modest headwind, but more than
overcome by those other factors. ?And can I follow up uh with the uh OPPS cuts for uh part B sort of infusion services?

Does that have any impact? I I know it doesn't really get consolidated into your results, but just thinking about SHILDs

Passages & reports (14)
  • Morning, Charles. Appreciate the question. Maybe I'll start with a little bit of backgroun…
  • know,
  • designed to support access to care for vulnerable patients by allowing those hospitals who…
  • participation, but it has endured given the criticality of the program's underlying purpos…
  • number of 340B contract pharmacies is far below that of the large retail pharmacy chains.
  • So
  • our exposure as a result is a small fraction of what those competitors would have or what …
  • a
  • relatively small contributor to overall Evernorth earnings. I'd also note that the contrib…
  • significant enough for us to call it out as a substantial headwind. And the continued mome…
  • for specialty and care of 8 to 12% per year. So we'll be toward the lower end of that. Aga…
  • overcome by those other factors.
  • And can
  • I follow up uh with the uh OPPS cuts for uh part B sort of infusion services? Does that ha…

Speaker unclear

?and sort of the work they do, would that have an impact for Shields at all, or is that an maybe

Passages & reports (1)
  • and sort of the work they do, would that have an impact for Shields at all, or is that an …

Speaker 6

an opportunity for

Passages & reports (1)
  • an opportunity for

Speaker unclear

?SHIELDS in

Passages & reports (1)
  • SHIELDS in

Speaker 7

helping

Passages & reports (1)
  • helping

Speaker 6

hospitals?

Passages & reports (1)
  • hospitals?

Speaker 2

Yeah, appreciate that question as well. So to your point, we have an investment position in SHIELDS, so it doesn't the underlying performance of the SHIELDS business does not consolidate into our income. Um we have essentially a preferred investment, so there's some um ?uh income from that, but it the underlying performance of the asset does not consolidate into our results. ?To the core of your question, though, when the 340 340B rules and regulations change and the program gets more complicated, the demand for SHIELD services actually increases.

So we've seen a lot of interest over the course of the last 12 to 24 months from hospitals and health systems who are seeking to optimize their
own in house pharmacies, their own in house specialty capabilities for the services that SHIELDS provides. And that the SHILES performance has ?been really outstanding the last couple of years when you look at the underlying performance and both the top and bottom line.

and a lot of that is many of these hospitals and health systems don't have the expertise in terms of inventory management, clinical coordination, accreditation services. So we're able to essentially support them via
Shields and there's some synergy relative to client opportunities and cross cells between our Evernorth portfolio and the SHIELDS client base. So broadly speaking that's how I would encourage you to think about the SHIELDS component. ?

Great,
that was really helpful.

Passages & reports (11)
  • Yeah, appreciate that question as well. So to your point, we have an investment position i…
  • uh
  • income from that, but it the underlying performance of the asset does not consolidate into…
  • To
  • the core of your question, though, when the 340 340B rules and regulations change and the …
  • own in house pharmacies, their own in house specialty capabilities for the services that S…
  • been
  • really outstanding the last couple of years when you look at the underlying performance an…
  • Shields and there's some synergy relative to client opportunities and cross cells between …
  • Great,
  • that was really helpful.

Speaker unclear

?Thanks, I appreciate the

Passages & reports (1)
  • Thanks, I appreciate the

Speaker 3

comments.

Passages & reports (1)
  • comments.

Speaker unclear

?Thank you.

Passages & reports (1)
  • Thank you.

Speaker 0

Our next question comes from Elizabeth Anderson with Evercore ISI. Yumi asked your question.

Passages & reports (1)
  • Our next question comes from Elizabeth Anderson with Evercore ISI. Yumi asked your questio…

Speaker 3

Hi ?guys, good morning, and thanks so much for the question. I had a question

Passages & reports (3)
  • Hi
  • guys, good
  • morning, and thanks so much for the question. I had a question

Speaker 4

about stop loss. Um, you know, obviously seeing some nice growth in in sort of middle market and and the premiums growing nicely there. Can you tell us a little bit more about like how stop loss is performing relative to the rural segment and sort of how your you know your current expectations for Jan 1 pricing versus trend ?you're seeing

Passages & reports (4)
  • about stop loss. Um, you know, obviously seeing some nice growth in in sort of middle mark…
  • Jan 1 pricing versus trend
  • you're
  • seeing

Speaker 3

there? Thank

Passages & reports (1)
  • there? Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Good morning, Elizabeth. I'll start and then hand it over to Ann to get into more of the specifics in terms of current performance and 27 implications. Big picture, our stop loss book is performing well. And in line with what we talked about before in terms of 26 and 27 being the years where we are increasing the margin profile in that book of business back to target levels.

Most of that has been accomplished here in 26 with the price actions we were able to secure, and I've been really pleased with the strong retention
?on that book of business, which speaks to the strong consultation, the sales and client management teams within Cigna Healthcare doing great ?work to ensure that we continue with those long-term relationships. ?But the overall stop loss book continues to perform well, and as we indicated earlier, that's one of the three enterprise tailwinds for 27 as we as we step into the new year.

And can you pick up a bit in terms of current year performance in the 27 price increases?

Passages & reports (8)
  • Good morning, Elizabeth. I'll start and then hand it over to Ann to get into more of the s…
  • we are increasing the margin profile in that book of business back to target levels. Most …
  • on
  • that book of business, which speaks to the strong consultation, the sales and client manag…
  • work
  • to ensure that we continue with those long-term relationships.
  • But
  • the overall stop loss book continues to perform well, and as we indicated earlier, that's …

Speaker 3

Sure. So as Brian said, ?in tracking in line with what we expected, as we talked about before, we've built out our analytics and clinical data so we can price at the right levels and also see early performance. And so those indicators are tracking well. I'll give you an example. Year to date, we've seen relatively stable frequency trends in high cost claimants across multiple attachment point levels.

And that's played out consistent with our expectations, but also consistent with what we observed last year. So when we put it all together, along with the other indicators we watch, we're feeling good about the stop loss book and where we expect to finish this year.

Passages & reports (4)
  • Sure. So as Brian said,
  • in
  • tracking in line with what we expected, as we talked about before, we've built out our ana…
  • high cost claimants across multiple attachment point levels. And that's played out consist…

Performance is in line with our pricing and planning and our margin recapture targets. And as Brian just mentioned, you know, our plan is ?you know, could we capture a portion of the margin over this year and a portion next year? So with our visibility into the performance this year, our expectations from next year, our pricing captures this objective, and we're executing well against the plan.

So we remain confident in our MCR
range for this year, including stop loss, and also executing on our the remainder of our margin recapture plan as we go through 27.

Passages & reports (4)
  • Performance is in line with our pricing and planning and our margin recapture targets. And…
  • you
  • know, could we capture a portion of the margin over this year and a portion next year? So …
  • range for this year, including stop loss, and also executing on our the remainder of our m…

Speaker unclear

?Great. Thank you very much.

Passages & reports (1)
  • Great. Thank you very much.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. Our next question comes from Wit Mayo with Leo Ring Partners. You may ask your question.

Passages & reports (1)
  • you. Our next question comes from Wit Mayo with Leo Ring Partners. You may ask your questi…

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 6

good morning.

Passages & reports (1)
  • good morning.

Speaker unclear

?This is Dean Randall Son for

Passages & reports (1)
  • This is Dean Randall Son for

Speaker 6

WIT.

Passages & reports (1)
  • WIT.

Speaker unclear

?After some noise surrounding Arkansas

Passages & reports (1)
  • After some noise surrounding Arkansas

Speaker 7

last year, you re-emphasized

Passages & reports (1)
  • last year, you re-emphasized

Speaker unclear

?the

Passages & reports (1)
  • the

Speaker 6

value ?of integrating PBM and pharmacy capabilities. With Tennessee moving in a similar direction being a bit of a different story considering ?a Credo's

Passages & reports (5)
  • value
  • of
  • integrating PBM and pharmacy capabilities. With Tennessee moving in a similar direction be…
  • a
  • Credo's

Speaker unclear

?Memphis

Passages & reports (1)
  • Memphis

Speaker 7

footprint. Has that at all changed how you think about Evernorth's operating model and the general flexibility you might need going forward? Thank

Passages & reports (1)
  • footprint. Has that at all changed how you think about Evernorth's operating model and the…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker unclear

?Great

Passages & reports (1)
  • Great

Speaker 2

morning, Stephen. I'll take that one. So stepping back, I think your question is about some of the state level activity relative to, I'll call it vertical integration for lack of a better term, just to put an umbrella term over ?it. As we talked about some of the prior questions here this morning, it's clear that our current healthcare system ?is on an unsustainable trajectory with affordability, fragmented patient experiences being common pain points.

And we're seeing some policymakers, legislators focusing on vertical integration as a potential root cause of these challenges in the healthcare system. Now, for us, we do not pursue integration for its own sake. Rather, we see tremendous benefits to
patients through connecting data with individual context, along with coordinating care across providers, plan designs, et cetera. ?And our lead-to-one vision is designed to drive personalization at scale. ?

And
as I said earlier, a particular emphasis on those with the most clinically complex health care needs and our integrated capabilities allow us to do this even better and more effectively. ?And we have strong evidence of improved affordability results and greater patient satisfaction when care is integrated and coordinated. For example, in our Health Sense Oncology patient solution. We provided a few examples of this during the Investor Day.

For example, the evidence showing that a cancer patient's integrated journey saves $28,000 per person per
?year, or $2,000 per person per year of savings for an integrated customer who has cardiodiabetesity. And it's not just affordability, it's also better health outcomes. For Signa Healthcare, our integrated customers show 12% lower A1C for people with diabetes. ?So these are all examples of our integrated model playing itself out in the form of improved affordability, better patient experiences, and improved health outcomes.

So we believe the current composition of the Cygna group and our three growth platforms Cigna Healthcare, Specialty and Care, Pharmacy Benefit Services is optimal, and we believe we're creating real
value for customers in the market and value for shareholders with the current composition of the Cygna

Passages & reports (17)
  • morning, Stephen. I'll take that one. So stepping back, I think your question is about som…
  • it.
  • As we talked about some of the prior questions here this morning, it's clear that our curr…
  • is
  • on an unsustainable trajectory with affordability, fragmented patient experiences being co…
  • patients through connecting data with individual context, along with coordinating care acr…
  • And
  • our lead-to-one vision is designed to drive personalization at scale.
  • And
  • as I said earlier, a particular emphasis on those with the most clinically complex health …
  • And
  • we have strong evidence of improved affordability results and greater patient satisfaction…
  • year,
  • or $2,000 per person per year of savings for an integrated customer who has cardiodiabetes…
  • So
  • these are all examples of our integrated model playing itself out in the form of improved …
  • value for customers in the market and value for shareholders with the current composition …

Speaker unclear

?Group.

Passages & reports (1)
  • Group.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. Our last question comes from Aaron Wright with Morgan Stanley. You may ask your question.

Passages & reports (1)
  • you. Our last question comes from Aaron Wright with Morgan Stanley. You may ask your quest…

Speaker unclear

?Great, thanks.

Passages & reports (1)
  • Great, thanks.

Speaker 4

At ?investor day, you talked about the next leg of growth and specialty, including greater opportunity across the medical benefit side as well as on the distribution side too. Are these drivers we think about for

Passages & reports (3)
  • At
  • investor
  • day, you talked about the next leg of growth and specialty, including greater opportunity …

Speaker unclear

?27 or are these drivers that we're thinking about more longer term or

Passages & reports (1)
  • 27 or are these drivers that we're thinking about more longer term or

Speaker 4

anything ?you can quantify on that front? Thanks.

Passages & reports (3)
  • anything
  • you can
  • quantify on that front? Thanks.

Speaker 2

Good morning, Aaron. Appreciate the question. You're right. Those are those are two specific areas that will continue to drive attractive growth in the specialty and care portfolio over time. And to the core of your question, distribution as well as the medical benefit are areas where we're comparatively underrepresented relative to the overall specialty space today. So if you if you think about our distribution capabilities, CureScript, today it's a $25 billion business.

So already sizable,
?and it's been growing double digits for many years in a row. Yet we see substantial opportunity to grow that even more rapidly in the future. So the introduction of our Evernorth wholesale capability that we talked about the Investor Day is one example of expanding our reach in the distribution space. And you heard from Matt Pearlberg at Investor Day, we expect $20 billion of net new revenue and distribution and specialty by 2030.

So $25 billion from today will go to $45 billion by 2030, reflecting that distribution expansion. 27 will not see an outsized benefit per se from that. You should think of it as more a gradual
build in that space over the course of the next three to four years. And on the medical benefit, to your point, when you step back, the specialty market in aggregate is call it a $480 billion addressable market.

Roughly 60% of that is direct to patient. That's
?where we have particularly strong capabilities, strong market share. Our credo specialty pharmacy has pointed there. We have attractive market share. We continue to win business in the market, but we're already strong in that space. The medical benefit, the other 40%, it's often provider-administered specialty medications. We have comparatively small share in that space with just six or seven percent.

Similar to just the distribution question, 27% will not see outsized growth in our specialty medical business. In the later years in the decade, when some of those biosimilars under the medical benefits start to hit, that's when we'll see an uptick in the growth rate there. So again, think
of biosimilars for oncology, biosimilars for MS. We'll start to see more of an uptick later in the decade.

So neither one of those are a specific outsized contributor to 27, but they're both exciting opportunities for our specialty and care portfolio to continue to perpetuate its growth.

Passages & reports (10)
  • Good morning, Aaron. Appreciate the question. You're right. Those are those are two specif…
  • overall specialty space today. So if you if you think about our distribution capabilities,…
  • and
  • it's been growing double digits for many years in a row. Yet we see substantial opportunit…
  • Matt Pearlberg at Investor Day, we expect $20 billion of net new revenue and distribution …
  • build in that space over the course of the next three to four years. And on the medical be…
  • where
  • we have particularly strong capabilities, strong market share. Our credo specialty pharmac…
  • just six or seven percent. Similar to just the distribution question, 27% will not see out…
  • of biosimilars for oncology, biosimilars for MS. We'll start to see more of an uptick late…

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. I will turn the call back over to Brian Devanko for closing remarks.

Passages & reports (1)
  • you. I will turn the call back over to Brian Devanko for closing remarks.

Speaker 2

Thank you very much, and thanks for all of those questions. Let me just close with this. It's an exciting time here at the Signa Group as our company unifies around a single vision, lead to one, ?and begins to compound the distinctive capabilities we've developed to capture the opportunity set in front of us. ?We have a clear strategic growth framework for creating long-term value and will continue to execute with discipline across the enterprise.

As we wrap up 2026 and look ahead to 27, We're energized by our strategy and execution momentum. We have a proven ability to lead and navigate change, and it's a privilege to do so
while serving our customers, patients, and shareholders. With that, I want to thank our team around the world for their commitment to our customers, for their partnership and collaboration, and for their adaptability. ?

Thank
you for your time today and your interest in the CINAG

Passages & reports (8)
  • Thank you very much, and thanks for all of those questions. Let me just close with this. I…
  • and
  • begins to compound the distinctive capabilities we've developed to capture the opportunity…
  • We
  • have a clear strategic growth framework for creating long-term value and will continue to …
  • while serving our customers, patients, and shareholders. With that, I want to thank our te…
  • Thank
  • you for your time today and your interest in the CINAG

Speaker unclear

?Group.

Passages & reports (1)
  • Group.

Speaker 0

Ladies and gentlemen, this concludes the CINAG Group's third quarter 2026 results review. Signet Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this call. You may access the recorded conference by dialing 866-405-7290 ?or 203-369-0603. There is no passcode required for this replay. Thank you for participating. We will now disconnect.

Passages & reports (4)
  • Ladies and gentlemen, this concludes the CINAG Group's third quarter 2026 results review. …
  • 866-405-7290
  • or
  • 203-369-0603. There is no passcode required for this replay. Thank you for participating. …
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

1 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 1. Unassigned words: 331. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T02:30:01.549Z.
Transcript version v1-080f77c7adbf24aff617 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.